Preliminary Report - ID Mapping

Traditionally the BioGRID repository has required that all curated data map to a peer-reviewed Pubmed ID before public release. With the rapidly evolving global health crisis of COVID-19, we've decided to temporarily suspend that requirement in order to more rapidly curate publications released on platforms such as BiorXiv and provide that data to the research community. As a result, some of our download files currently require a Pubmed ID to output correctly (such as PSI-MI TAB, BioGRID TAB2, and PSI-MI XML). We recommend anyone wanting to get the most accurate download available to please use our newest TAB3 format instead.

In order to maintain compatibility, we've temporarily assigned new custom IDs in place of Pubmed IDs for each of these publications. So, if you see one of these IDs, you can use the following listing to determine the associated DOI for each.

WARNING - Please treat these papers with caution as they are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.

Custom ID DOI AUTHOR DATASET
888800000002 10.1101/2020.03.29.20041962 Gao T (2020) Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation
888800000003 10.1101/2020.02.16.951723 Sun C (2020) SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development
888800000005 10.1101/2020.03.14.988345 Wang K (2020) SARS-CoV-2 invades host cells via a novel route: CD147-spike protein
888800000006 10.1101/2020.02.17.951848 Zhou Q (2020) Structure of dimeric full-length human ACE2 in complex with B0AT1
888800000007 10.1101/2020.02.26.964882 Jin Z (2020) Structure of Mpro from COVID-19 virus and discovery of its inhibitors [DEPRECATED PUBLICATION]
888800000008 10.1101/2020.03.29.013490 Wang C (2020) Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2
888800000009 10.1101/2020.03.25.996348 Dai W (2020) Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease
888800000010 10.1101/2020.03.15.992883 Joyce MG (2020) A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein
888800000011 10.1101/2020.03.16.993386 Gao Y (2020) Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target
888800000012 10.1101/2020.03.31.019216 Liang Q (2020) Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis
888800000013 10.1101/2020.04.15.042085 Bestle D (2020) TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets
888800000016 10.1101/2020.04.14.042010 Chi X (2020) Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain
888800000017 10.1101/2020.04.06.20055475 Ye L (2020) Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor
888800000018 10.1101/2020.04.19.049643 Zeng X (2020) Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy
888800000019 10.1101/2020.04.23.057265 Peng Q (2020) Structural and biochemical characterization of nsp12-nsp7-nsp8 core polymerase complex from COVID-19 virus
888800000020 10.1101/2020.04.22.046565 Liu Y (2020) Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2
888800000021 10.1101/2020.04.21.053017 Walker A (2020) Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases
888800000022 10.1101/2020.04.17.047498 Rosas Lemus M (2020) The crystal structure of nsp10-nsp16 heterodimer from SARS CoV-2in complex with S-adenosylmethionine
888800000025 10.1101/2020.04.29.068890 Rut W (2020) Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 drug design
888800000029 10.1101/2020.05.02.20086876 Zhang D (2020) Ultra-fast and onsite interrogation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in environmental specimens via surface enhanced Raman scattering (SERS)
888800000031 10.1101/2020.05.06.079830 Zha L (2020) Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles
888800000032 10.1101/2020.05.02.043554 Gunther S (2020) Catalytic cleavage of HEAT and subsequent covalent binding of the tetralone moiety by the SARS-CoV-2 main protease
888800000033 10.1101/2020.05.01.20077743 Wu Y (2020) A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
888800000034 10.1101/2020.05.03.074914 Liu X (2020) Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection
888800000035 10.1101/2020.05.21.109157 Lui I (2020) Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity
888800000036 10.1101/2020.05.21.107870 Partridge LJ (2020) Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line
888800000037 10.1101/2020.05.13.092478 Chiodo F (2020) Novel ACE2-Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins and Lung Microbiota
888800000038 10.1101/2020.05.12.091298 Seydoux E (2020) Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual
888800000039 10.1101/2020.05.21.107565 Zang J (2020) Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
888800000040 10.1101/2020.05.12.092171 Zhou X (2020) Structure of SARS-CoV-2 main protease in the apo state reveals the inactive conformation
888800000041 10.1101/2020.06.17.156455 Stukalov A (2020) Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV
888800000042 10.1101/2020.06.05.135921 Bertoglio F (2020) SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
888800000043 10.1101/2020.06.05.135699 Moustaqil M (2020) SARS-CoV-2 proteases cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species and the search for reservoir hosts.
888800000045 10.1101/2020.06.05.134114 Daly JL (2020) Neuropilin-1 is a host factor for SARS-CoV-2 infection
888800000046 10.1101/2020.06.17.158121 Cubuk J (2020) The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA
888800000048 10.1101/2020.06.02.130161 Hanke L (2020) An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
888800000049 10.1101/2020.06.17.156471 Conceicao C (2020) The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins
888800000050 10.1101/2020.06.07.138677 Luan X (2020) Structure Basis for Inhibition of SARS-CoV-2 by the Feline Drug GC376
888800000051 10.1101/2020.06.02.129098 Lv Z (2020) Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
888800000052 10.1101/2020.06.06.137513 Lou Y (2020) Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries
888800000054 10.1101/2020.06.16.155812 Li J (2020) Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin
888800000055 10.1101/2020.06.15.153387 Beddingfield B (2020) The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection
888800000056 10.1101/2020.06.16.154708 Hanson QM (2020) Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
888800000057 10.1101/2020.06.09.20127050 Gniffke EP (2020) Plasma from recovered COVID19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay
888800000060 10.1101/2020.07.01.182659 Lu J (2020) High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity
888800000062 10.1101/2020.07.04.187757 Yurkovetskiy L (2020) Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
888800000063 10.1101/2020.07.31.230730 Cao W (2020) Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction
888800000064 10.1101/2020.07.24.219857 Esparza TJ (2020) High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme
888800000065 10.1101/2020.07.25.221036 Shilts J (2020) No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor
888800000066 10.1101/2020.07.13.201517 Davies JP (2020) Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies
888800000067 10.1101/2020.07.31.229781 Alitongbieke G (2020) Study on beta-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2
888800000068 10.1101/2020.07.31.231746 Glasgow A (2020) Engineered ACE2 receptor traps potently neutralize SARS-CoV-2
888800000069 10.1101/2020.07.27.224089 Beasley MD (2020) Antibodies that potently inhibit or enhance SARS-CoV-2 spike protein-ACE2 interaction isolated from synthetic single-chain antibody libraries
888800000070 10.1101/2020.07.29.227462 Gao C (2020) SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors
888800000071 10.1101/2020.07.26.222026 Zheng Y (2020) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) Protein Inhibits Type I and III Interferon Production by Targeting RIG-I/MDA-5 Signaling
888800000072 10.1101/2020.07.30.229187 Shi W (2020) A dynamic regulatory interface on SARS-CoV-2 RNA polymerase
888800000074 10.1101/2020.07.29.226761 ElBaba TJ (2020) Allosteric inhibition of the SARS-CoV-2 main protease - insights from mass spectrometry-based assays
888800000075 10.1101/2020.07.15.204404 Schmidt N (2020) A direct RNA-protein interaction atlas of the SARS-CoV-2 RNA in infected human cells
888800000076 10.1101/2020.08.03.234914 Cao L (2020) De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
888800000077 10.1101/2020.07.27.223727 Sacco MD (2020) Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L
888800000078 10.1101/2020.07.17.208959 Fu Z (2020) Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules
888800000079 10.1101/2020.07.31.231282 Tee KL (2020) Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay
888800000080 10.1101/2020.07.25.220806 Temerozo JR (2020) The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells and decrease the production of proinflammatory cytokines in infected cells.
888800000081 10.1101/2020.08.03.234559 Addetia A (2020) SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98
888800000082 10.1101/2020.08.28.272955 Laurent E (2020) Global BioID-based SARS-CoV-2 proteins proximal interactome unveils novel ties between viral polypeptides and host factors involved in multiple COVID19-associated mechanisms
888800000083 10.1101/2020.08.20.259770 Lapointe CP (2020) Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome inhibits translation initiation
888800000084 10.1101/2020.08.16.252973 Han L (2020) SARS-CoV-2 ORF9b Antagonizes Type I and III Interferons by Targeting Multiple Components of RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING Signaling Pathways
888800000085 10.1101/2020.08.06.238915 Watson A (2020) Peptide Antidotes to SARS-CoV-2 (COVID-19)
888800000086 10.1101/2020.08.12.247767 Yang Z (2020) Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2
888800000087 10.1101/2020.08.12.246389 Risner K (2020) Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture
888800000088 10.1101/2020.08.08.238469 Schoof M (2020) An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation
888800000089 10.1101/2020.08.14.250258 Chen Y (2020) Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro
888800000090 10.1101/2020.08.09.242917 Thepaut M (2020) DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist
888800000091 10.1101/2020.08.07.241877 Hassert M (2020) mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2
888800000092 10.1101/2020.08.09.243451 Yuan S (2020) Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA.
888800000093 10.1101/2020.08.18.256776 Andres AD (2020) SARS-CoV-2 ORF9c Is a Membrane-Associated Protein that Suppresses Antiviral Responses in Cells
888800000094 10.1101/2020.08.13.249177 Carrique L (2020) The SARS-CoV-2 Spike harbours a lipid binding pocket which modulates stability of the prefusion trimer
888800000095 10.1101/2020.08.13.248211 Baddock HT (2020) Characterisation of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification
888800000096 10.1101/2020.08.10.244525 Malla TN (2020) Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals
888800000097 10.1101/2020.08.11.244863 Pillon MC (2020) Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15
888800000098 10.1101/2020.08.12.247338 Wang C (2020) Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection
888800000099 10.1101/2020.08.14.251421 Wilamowski M (2020) Methylation of RNA Cap in SARS-CoV-2 captured by serial crystallography
888800000100 10.1101/2020.08.13.248872 Wei C (2020) SARS-CoV-2 manipulates the SR-B1-mediated HDL uptake pathway for its entry
888800000101 10.1101/2020.08.14.251207 Heaton BE (2020) SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2
888800000102 10.1101/2020.08.07.20169441 Johari YB (2020) Production of Trimeric SARS-CoV-2 Spike Protein by CHO Cells for Serological COVID-19 Testing
888800000103 10.1101/2020.08.09.242867 Gai J (2020) A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential
888800000104 10.1101/2020.09.03.282103 Samavarchi-Tehrani P (2020) A SARS-CoV-2 - host proximity interactome
888800000105 10.1101/2020.09.09.287508 Gu Y (2020) Interaction network of SARS-CoV-2 with host receptome through spike protein
888800000106 10.1101/2020.08.29.273441 Bojadzic D (2020) Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike - ACE2 Protein-Protein Interaction - A Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19
888800000107 10.1101/2020.09.04.282558 Bouwman KM (2020) Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins
888800000108 10.1101/2020.08.28.271601 Dash P (2020) Sequence analysis of Indian SARS-CoV-2 isolates shows a stronger interaction of mutated receptor binding domain with ACE2 receptor
888800000109 10.1101/2020.08.28.269175 St-Germain JR (2020) A SARS-CoV-2 BioID-based virus-host membrane protein interactome and virus peptide compendium: new proteomics resources for COVID-19 research
888800000111 10.1101/2020.09.04.280081 Qiang X (2020) Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction.
888800000112 10.1101/2020.09.09.287987 Durdagi S (2020) Near-Physiological-Temperature Serial Femtosecond X-ray Crystallography Reveals Novel Conformations of SARS-CoV-2 Main Protease Active Site for Improved Drug Repurposing
888800000113 10.1101/2020.09.01.277954 Bartolome A (2020) Angiotensin converting enzyme 2 is a novel target of the secretase complex
888800000114 10.1101/2020.08.31.274704 Guo L (2020) Engineered Trimeric ACE2 Binds and Locks "Three-up" Spike Protein to Potently Inhibit SARS-CoVs and Mutants
888800000115 10.1101/2020.09.09.289488 Kotani N (2020) Candidate screening of host cell membrane proteins involved in SARS-CoV-2 entry
888800000116 10.1101/2020.08.27.270637 Flower TG (2020) Structure of SARS-CoV-2 ORF8, a rapidly evolving coronavirus protein implicated in immune evasion
888800000117 10.1101/2020.09.21.307439 Wang X (2020) Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution
888800000118 10.1101/2020.09.14.295956 Lin C (2020) Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction
888800000119 10.1101/2020.09.16.297366 Sagar S (2020) Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells
888800000120 10.1101/2020.09.18.301952 Xiao T (2020) A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro
888800000121 10.1101/2020.09.16.297945 Meyer B (2020) Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets for drug repurposing
888800000122 10.1101/2020.09.22.308338 Wagner TR (2020) NeutrobodyPlex - Nanobodies to monitor a SARS-CoV-2 neutralizing immune response
888800000123 10.1101/2020.09.20.297242 Ren W (2020) Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry
888800000124 10.1101/2020.09.13.295691 Olaleye OA (2020) Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2.
888800000125 10.1101/2020.09.16.300319 Tada T (2020) A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2 infection in cell culture
888800000126 10.1101/2020.09.16.299891 Higuchi Y (2020) High affinity modified ACE2 receptors prevent SARS-CoV-2 infection
888800000127 10.1101/2020.09.16.20190694 Ichimura T (2020) KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney
 
covid/unpublished.txt · Last modified: 2020/11/06 19:05 by biogridadmin